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http://dx.doi.org/10.1016/j.ccr.2013.02.017SUMMARYWe performed a loss-of-function RNA interference screen to define therapeutic targets in multiple myeloma,
a genetically diverse plasma cell malignancy. Unexpectedly, we discovered that all myeloma lines require
caspase-10 for survival irrespective of their genetic abnormalities. The transcription factor IRF4 induces
both caspase-10 and its associated protein cFLIPL in myeloma, generating a protease that does not induce
apoptosis but rather blocks an autophagy-dependent cell death pathway. Caspase-10 inhibits autophagy by
cleaving the BCL2-interacting protein BCLAF1, itself a strong inducer of autophagy that acts by displacing
beclin-1 from BCL2. While myeloma cells require a basal level of autophagy for survival, caspase-10 tempers
this response to avoid cell death. Drugs that disrupt this vital balance may have therapeutic potential in
myeloma.INTRODUCTION
Multiple myeloma is a malignant proliferation of plasma cells in
the bone marrow. Autologous stem cell transplantation and
drugs such as lenalidomide and bortezomib have improved
survival, yet myeloma remains largely incurable. One of the chal-
lenges in treating myeloma is its genomic and phenotypic
heterogeneity (Kuehl and Bergsagel, 2012). Hence, an optimal
therapy in myeloma would be one that targets an essential regu-
latory pathway in all subtypes of this cancer.
RNA interference screening can systematically identify genes
and pathways that are essential for cancer cell proliferation and
survival (Ngo et al., 2006). In some instances, these screens
identify pathways that are affected by somatic mutations,
thereby revealing ‘‘oncogene addiction.’’ In other cases, these
screens identify essential genes that are not affected by struc-
tural abnormalities, a phenomenon dubbed ‘‘nononcogene
addiction’’ (Luo et al., 2009). In myeloma, one such nononco-Significance
A variety of translocations, mutations, and copy number alter
Faced with this genetic diversity, it is imperative that we des
all myeloma subtypes. Using an unbiased genetic screen we d
caspase-10 for survival. This instance of ‘‘nononcogene addic
required to maintain myeloma cell viability. Caspase-10 modu
cell death. Therapies targeting caspase-10 would exploit this
myeloma subtypes.gene addiction target is the transcription factor IRF4, which is
required for the survival of all genetic subtypes of this cancer
(Shaffer et al., 2008). Although the oncogene MYC is an impor-
tant IRF4 target in myeloma, other targets must contribute to
IRF4 addiction in myeloma.
Following ligand engagement of certain members of the
tumor necrosis factor receptor superfamily, caspase-10 and
its paralogue caspase-8 initiate a form of programmed cell
death known as apoptosis (Wang et al., 2001; Wilson et al.,
2009). The recruitment of these caspases to membrane-associ-
ated ‘‘DISC’’ complexes induces their autoproteolysis,
releasing p10/p18 dimers that initiate apoptosis by activating
effector caspases. However, caspase-10 and caspase-8 have
functions in addition to their pro-apoptotic role. Both proteins
can activate the NF-kB pathway when overexpressed (Chaudh-
ary et al., 2000), and caspase-8 deficiency is associated with
defective T cell activation and immunodeficiency in humans
and mice (Chun et al., 2002; Salmena et al., 2003). Duringations drive the malignant phenotype of multiple myeloma.
ign therapeutics to attack vulnerabilities that are shared by
iscovered that all multiple myeloma subtypes tested require
tion’’ appears to stem from a basal level of autophagy that is
lates this autophagic response, preventing it from inducing
regulatory pathway and could have broad efficacy across
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Caspase-10 Addiction in MyelomaT cell activation, macroautophagy (hereafter referred to as
autophagy) is activated to meet the increased bioenergetic
requirements of cell proliferation, but this autophagy is kept
in check by caspase-8 (Bell et al., 2008; Hubbard et al.,
2010; Yu et al., 2004).
Autophagy is a cellular process in which portions of the cytosol
or entire organelles are sequestered into double membrane vesi-
cles termed autophagosomes and subsequently fused with the
lysosome, where the content is digested and recycled (Levine
and Kroemer, 2008; Rabinowitz and White, 2010). Autophagy
is essential to maintain cell homeostasis, recycle damaged
organelles, and overcome nutrient deprivation and metabolic
stress. However, autophagy can be associated with a nonapop-
totic form of cell death (Galluzzi et al., 2012), and hence this
cellular reaction to stress must be tightly regulated (Bell et al.,
2008; Shimizu et al., 2004; Yu et al., 2004). One level of regulation
is dictated by the abundance of anti-apoptotic Bcl-2 family
proteins, which sequester beclin-1, a key inducer of autophagy
(Pattingre et al., 2005).
In addition to its regulation of autophagy, caspase-8 blocks
a form of regulated necrosis by preventing the activation of RIP
kinase 3 (RIPK3) (Green et al., 2011). This regulatory pathway
appears to require two caspase-8-interacting proteins, FADD
and the caspase-like protein cFLIPL, forming a protease with
limited activity that can block necrosis but cannot initiate
apoptosis. cFLIPL pairs with caspase-8 and prevents its auto-
cleavage while itself being a substrate of caspase-8, resulting
in a caspase-8 complex containing a p43 cFLIP isoform (Budd
et al., 2006).
Here, we report an RNA interference-based genetic screen to
discover therapeutic targets in genetically heterogeneous
multiple myeloma cells, but not in lymphoma cells.
RESULTS
Caspase-10 Is Essential for Myeloma Viability
To uncover essential pathways required for myeloma
proliferation and survival, we performed a loss-of-function
RNA interference screen using a retroviral library to inducibly
express short hairpin RNAs (shRNAs) (Ngo et al., 2006). An
shRNA-targeting caspase-10 was depleted during a 3-week
culture of three myeloma cell lines, indicating its toxicity, but
had no effect in four lymphoma lines (Figure 1A). To extend
this finding, we cloned this shRNA and five additional
caspase-10 shRNAs (Figure 1B; Figures S1A and S1B available
online) into a retroviral vector that allows coexpression of green
fluorescent protein (GFP). In myeloma lines transduced with
these vectors, the fraction of GFP+/shRNA+ cells declined
over time, but no toxicity was observed in lymphoma lines
(Figures 1C, S1C, and S1D). One caspase-10 shRNA (#1)
targets a sequence unique to the D splice isoform (Figure 1B),
indicating its essential role in myeloma. The toxicity of this
shRNA could be rescued by ectopic provision of a TAP-tagged
caspase-10 isoform D that is resistant to this shRNA
(TAP-Casp10*), showing that the toxicity of this shRNA for
myeloma cells was not due to off-target effects (Figure 1D).
Of note, caspase-10 shRNAs were toxic to all myeloma cell
lines tested, regardless of their various oncogenic aberrations
(Figure 1C).436 Cancer Cell 23, 435–449, April 15, 2013 ª2013 Elsevier Inc.Myeloma Viability Depends on Caspase-10 Catalytic
Activity
To determine if the prosurvival effect of caspase-10 in myeloma
requires its protease activity, we generated a protease-dead
version of the caspase-10 D isoform in which the catalytic site
cysteine was replaced by serine. Wild-type and protease-dead
caspase-10 were cloned into a doxycycline-inducible vector
that coexpresses GFP, allowing the abundance of caspase-10-
transduced cells to bemonitored over time (Figure 2A). After cas-
pase-10 induction, myeloma cells expressing the protease-dead
mutant were killed whereas those overexpressing wild-type cas-
pase-10 were not, suggesting that protease-dead caspase-10
functions in a dominant negative fashion to induce cell death.
Consistent with this hypothesis, myeloma lines had readily
detectable proteolytic activity for the caspase-10 substrate
AEVD-pNA, but this was not a feature of lymphoma cell lines
(Figure 2B). This proteolytic activity was inhibited by the broad-
spectrum caspase inhibitor Q-VD-OPH and a more selective
caspase-10 inhibitor Q-AEVD-OPH (Figure 2B). Because the
selectivity of synthetic caspase inhibitors is not absolute
(McStay et al., 2008; Walsh et al., 2011), we further assessed
whether caspase-10 was responsible for the observed proteo-
lytic activity. First, immunoprecipitated caspase-10 from
different myeloma cell lines had proteolytic activity for AEVD-
pNA (Figure S2A). Furthermore, this proteolytic activity was
decreased when caspase-10 was knocked down by RNA inter-
ference in myeloma cells (Figure S2B). Together, these data indi-
cate that the elevated AEVD-pNA cleavage observed in
myeloma cells is largely due to caspase-10 activity.
The caspase inhibitors Q-VD-OPH and Q-AEVD-OPH killed
myeloma lines in a time-dependent manner but did not kill the
lymphoma line HBL1 (Figure 2C). Because stromal cells are
known to protect myeloma cells from the lethal effect of certain
cytotoxic agents (Hideshima and Anderson, 2002), we investi-
gated whether the stromal line HS-5 would mitigate the effect
of caspase inhibitors on myeloma viability (Figure 2D). Whereas
the toxic effect of dexamethasone was blocked by coculture
with HS-5 cells, the caspase-10 inhibitor Q-AEVD-OPH was still
able to kill themyeloma cells while not affecting the viability of the
stromal cells (data not shown). Finally, we isolated CD138+
neoplastic cells from patients with newly diagnosed myeloma
and cocultured the neoplastic cells with HS-5 cells for 16 hr
before adding Q-AEVD-OPH, Q-VD-OPH, or DMSO. The cas-
pase inhibitors decreased the number of viable myeloma cells
in a time-dependent fashion (Figure 2E).
Because caspase-8 and caspase-10 share structural and
functional similarities, we examined whether caspase-8 might
also regulate myeloma viability. Two shRNAs targeting cas-
pase-8 reduced its expression by 50% but were not toxic in
the RNA interference screen (Figures S2C and S2D). To test if
caspase-10 might function redundantly with caspase-8, we
knocked down caspase-10 expression in myeloma lines and
then treated them with a caspase-8 inhibitor (IETD-OPH) that
does not inhibit caspase-10. As expected, caspase-10 knock-
down was toxic, but inhibition of caspase-8 activity did not
increase this toxicity, even though this inhibitor did reduce
Fas-mediated apoptosis (Figure S2E). We conclude that cas-
pase-10, but not caspase-8, maintains the viability of myeloma
cells.
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Figure 1. Caspase-10 Knockdown Is Toxic for All Myeloma Cell Lines
(A) Caspase-10 shRNA toxicity in an RNA interference screen was quantified as the ratio of shRNA abundance in shRNA-uninduced cells at time 0 versus shRNA-
induced cells after 21 days. Data represent the mean ± SEM of four independent experiments.
(B) Caspase-10 protein level in the SKMM1myeloma line 4 days after the expression of two caspase-10 shRNAs (shCasp10-1, shCasp10-2). Caspase-10 A andD
isoforms are indicated.
(C) The indicated cell lines were infected with retroviruses coexpressing shCasp10-1 or shCasp10-2 and GFP. The percentage of GFP+ cells was measured over
time by flow cytometry and normalized to the percentage of GFP+ cells before retroviral transduction.
(D) SKMM1 cells were infected with a retrovirus expressing a TAP-tagged caspase-10 isoform D carrying mutations in the shCasp10-1 target sequence
(TAP-Casp10*) or with an empty vector. The toxicities of shCasp10-1 and a control shRNA were measured as in (C). The endogenous caspase-10 and the
TAP-Casp10* protein levels are shown in the right panel.
See also Figure S1.
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Caspase-10 Addiction in MyelomaCaspase-10 Inhibition of Autophagic Cell Death in
Myeloma
While the proportions of myeloma cells in the G1, S, and G2/M
phases of the cell cycle were not affected by caspase-10 knock-
down, the number of dead cells, as identified by sub-G1 DNA
content, increased 3.5-fold (Figure 3A). Two hallmarks of
apoptosis, phosphatidylserine exposure and caspase-3 activa-
tion, were not induced upon caspase-10 knockdown, but were
induced following Fas crosslinking, as expected (Figure 3B).Moreover, treatment of myeloma cells with the caspase inhibitor
Q-VD-OPH did not induce other apoptotic features, including
cleavage of PARP, p23 (PTGES3), and caspase-7, but the
apoptosis inducer etoposide did (Figure S3A). These experi-
ments indicate that caspase-10 inhibits a nonapoptotic form of
cell death in myeloma cells.
Ultrastructural analysis of UTMC2 myeloma cells treated with
Q-VD-OPH or Q-AEVD-OPH revealed typical morphological
features of autophagy (Figure 3C). By 12 hr after Q-VD-OPHCancer Cell 23, 435–449, April 15, 2013 ª2013 Elsevier Inc. 437
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Figure 2. Caspase-10 Catalytic Activity Is Essential to Myeloma Survival
(A) The indicated myeloma lines were infected with a retrovirus coexpressing GFP with caspase-10 isoform D, either as the wild-type or protease-dead mutant.
The percentage of GFP+ cells was normalized to the percentage before retroviral transduction.
(B) Caspase-10 activity in the indicated lines (left panel) and in KMS12 myeloma cells treated for 3 hr as indicated (right panel) was determined using an AEVD-
pNA colorimetric assay. Shown are mean ± SEM from triplicates.
(C) The indicated cell lines were treated with the caspase inhibitors Q-VD-OPH or Q-AEVD-OPH for the indicated times. Live cells (calcein+, PI) were quantified
by FACS using flow count fluorospheres (representative of three experiments).
(D) The indicated myeloma lines were cultured alone or together with GFP-expressing HS-5 stromal cells for 16 hr. Cells were then exposed to Q-AEVD-OPH
(25 mM) or dexamethasone (DEX, 0.5 mM) and the relative number of live myeloma cells (GFP, PI) was monitored by FACS.
(E) CD138+ primary myeloma cells were cocultured with HS-5 stromal cells for 16 hr before adding 25 mM Q-AEVD-OPH or Q-VD-OPH, or DMSO. The relative
number of viable myeloma cells was quantified by FACS.
See also Figure S2.
Cancer Cell
Caspase-10 Addiction in Myelomatreatment, early autophagosomes with double membranes
accumulated as did a limited number of autophagic vacuoles.
After 24 to 72 hr, large autophagic vacuoles containing disinte-
grated cellular structures appeared in the cytosol. The accumu-
lation of autophagic vacuoles was accompanied by fewer intra-
cellular organelles over time. By 48 hr, the endoplasmic
reticulum network was barely visible and the mitochondria that
remained were highly condensed. The characteristic hallmarks
of apoptosis were absent (e.g., membrane blebbing, nuclear
condensation), consistent with a nonapoptotic form of cell death.
Similar results were obtained when caspase-10 was depleted
using two different shRNAs (Figure S3B). Of note, autophagic438 Cancer Cell 23, 435–449, April 15, 2013 ª2013 Elsevier Inc.vesicles were present at a low level in untreated myeloma cells
(Figures 3C and S3B), suggesting that autophagy is active at
a basal rate in myeloma (see below).
To quantify autophagy and evaluate further the effect of cas-
pase-10 inhibition on the formation of autophagosomes,
myeloma cells were infected with a retrovirus expressing the
autophagosome-associated protein LC3 fused to GFP. Upon
initiation of autophagy, LC3 relocates from the cytosol to auto-
phagosomemembranes, where it plays a role in autophagosome
enlargement (Reggiori and Klionsky, 2002), and cytosolic LC3
(LC3-I, 18 kDa) undergoes C-terminal proteolytic processing to
a 16 kDa isoform, LC3-II. Autophagy is thus characterized by
Cancer Cell
Caspase-10 Addiction in Myelomathe accumulation of GFP-LC3 in punctate structures and by an
increase in LC3-II levels (Kabeya et al., 2000). Treatment of
two myeloma lines with Q-VD-OPH induced a time-dependent
redistribution of GFP-LC3 into punctate vesicles, in association
with cell death (Figure S3C). By day 5, GFP-LC3 punctate struc-
tures were present in over 60% of caspase inhibitor-treated cells
but in fewer than 5% of DMSO-treated cells.
We next wished to track autophagic flux induced by caspase-
10 inhibition by distinguishing between early autophagosomes
and later stepswhen these structures fusewith lysosomes, using
a tandemGFP-mCherry-tagged LC3 (Kimura et al., 2007; Pankiv
et al., 2007). Within the acidic lysosome, GFP fluorescence is
quenched whereasmCherry fluorescence is stable. Hence, early
autophagosomes produce yellow signals (green plus red)
whereas autolysosomes produce red signals. Following expo-
sure to the caspase inhibitor Q-VD-OPH, many myeloma cells
developed overlapping green and red punctate structures by
4 hr and thus were engaged in an early phase of autophagy,
but by 16 hr, most cells had only red puncta, indicating autolyso-
some formation (Figure 3D). Similarly, knockdown of caspase-10
expression induced both yellow and red puncta, as did the auto-
phagy inducer rapamycin (Figure S3D). In contrast, DMSO-
treated myeloma cells had diffuse green and red fluorescence
as well as a few yellow and red punctate structures, consistent
with a low degree of basal autophagy. Q-VD-OPH had no effect
on control OCI-Ly19 lymphoma cells. Of note, the cell death
induced by Q-VD-OPH did not cause chromatin condensation,
as was evident in etoposide-treated cells undergoing apoptosis
(Figure S3D). To quantify autophagic responses in myeloma, we
used flow cytometry to monitor GFP and mCherry fluorescence
in live cells following treatment with the caspase inhibitor Q-VD-
OPH or DMSO (Figure S3E) (Hundeshagen et al., 2011). After
36 hr of Q-VD-OPH treatment, GFP fluorescence decreased
while the mCherry signal was stable, indicating that autophagy
had started and that some autophagosomes had already fused
with the lysosomes. By 48 hr, both green and red signals faded,
consistent with full degradation of the GFP-mCherry-LC3 fusion
protein in the lysosome over time. Another way to assess auto-
phagic flux through the lysosome is to monitor GFP-LC3 by
immunoblotting because initial lysosomal processing of GFP-
LC3 releases an isolated GFP domain. Treatment of myeloma
cells with Q-VD-OPH increased GFP cleavage, consistent with
increased autophagic flux and lysosomal fusion (Figure S3F).
To further evaluate LC3-II degradation in the lysosome, we
used bafilomycin A1, which inhibits lysosomal acidification, as
well as the lysosomal protease inhibitors pepstatin A and
E64d. The LC3-II levels in myeloma cells were increased by Q-
VD-OPH treatment, and these levels were further elevated by
concurrent treatment with bafilomycin A1 or with lysosomal
protease inhibitors (Figures 3E and S3G). Of note, both bafilomy-
cin A1 and the lysosomal protease inhibitors increased LC3-II
levels in myeloma cells even without caspase inhibition, consis-
tent with a low level of basal autophagy. These data show that
caspase-10 inhibition stimulates autophagic flux in myeloma
cells by increasing the formation of autophagosomes that, over
time, form autolysosomes.
We next tested whether the autophagic pathway is required
for the death of myeloma cells following caspase-10 inhibition.
Knockdown of the autophagy-related protein ATG5 decreasedthe induction of autophagy, as judged by LC3 processing (Fig-
ure 3F), and cell death induced by caspase inhibitors (Figure 3G).
Similarly, knockdown of beclin-1 reduced Q-VD-OPH-induced
death at an early time point (day 5), but depletion of beclin-1
was itself toxic at later time points (Figure 3G). Moreover, knock-
down of caspase-10 was less toxic in myeloma cells induced to
express shRNAs targeting the autophagy regulators beclin-1 or
ATG5 than in cells expressing a control shRNA (Figure 3H).
Hence, ATG5 and beclin-1 are important for the induction of
cell death following caspase-10 inhibition, demonstrating that
caspase-10 limits an autophagy-dependent death pathway in
myeloma.
The fact that beclin-1 depletion was toxic for myeloma lines
over time suggested that a basal level of autophagy is needed
to maintain myeloma survival, as previously suggested (Hoang
et al., 2009). Indeed, inhibition of autophagy using 3-methylade-
nine decreased the viability of all myeloma lines tested, but had
no effect on lymphoma lines (Figure 3I).
IRF4 Drives Caspase-10 and cFLIPL Expression in
Myeloma
We next wondered why myeloma cells are uniquely reliant upon
caspase-10 activity. Caspase-10 protein is highly expressed in
myeloma lines, with little if any expression in lymphoma lines
(Figure 4A). Moreover,CASP10mRNA levels are higher in normal
bone marrow-derived plasma cells than in resting peripheral
blood B cells (Figure 4B). Given that IRF4 is a master transcrip-
tion factor specifying the myeloma and plasma cell phenotype
(Shaffer et al., 2008), we hypothesized that IRF4 might transacti-
vate CASP10. Indeed, knockdown of IRF4 in a myeloma cell line
substantially reducedCASP10mRNA and protein levels (Figures
4C and S4A). Chromatin immunoprecipitation (ChIP) followed by
high-throughput DNA sequencing (ChIP-Seq) revealed that IRF4
binds to three regions of theCASP10 locus in a myeloma line but
not in a control lymphoma line that lacks IRF4 expression, which
was confirmed by conventional ChIP (NCBI Geo ID SRA025850;
Yang et al., 2012; Figures S4B and S4C). The IRF4 peaks were
centered over repeats of an IRF4 DNA binding motif (GAAA or
TTTC). We conclude IRF4 upregulates CASP10 expression in
normal and malignant plasma cells.
Another gene that is induced by IRF4 in myeloma cells is
CFLAR, which encodes the caspase-like protein cFLIP (Shaffer
et al., 2008). ChIP analyses confirmed that IRF4 binds to
a promoter-proximal region in the CFLAR first intron (Figures
S4D and S4E), coinciding with evolutionarily conserved tandem
IRF4 binding motifs (TTTC). TwoCFLAR splice variants exist that
encode a 55 kDa isoform (cFLIPL) and a 28 kDa isoform (cFLIPS).
Both variants can block death receptor-induced apoptosis by
heterodimerizing with caspase-8 and caspase-10, but cFLIPL
has additional signaling functions, including a positive role in
antigen-induced proliferation of T cells. cFLIPL was the predom-
inant isoform in myeloma lines whereas cFLIPS was more abun-
dant in lymphoma lines (Figure 4D).
Function of cFLIPL in Myeloma
Because IRF4 upregulates both caspase-10 and cFLIPL in
myeloma, we investigated whether their heterodimerization
might play a role in caspase-10 function in these cells. An shRNA
targeting both cFLIPL and cFLIPS was toxic for all myeloma linesCancer Cell 23, 435–449, April 15, 2013 ª2013 Elsevier Inc. 439
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Caspase-10 Addiction in Myelomatested but not for lymphoma lines (Figures 4E and S4F). This
effect on myeloma viability was due to modulation of cFLIP
because ectopic expression of cFLIPL rescued the SKMM1
myeloma line from the toxicity of the cFLIP shRNA (Figure S4G).
Immunoprecipitation of endogenous caspase-10 in KMS12
myeloma cells enriched for cFLIPL and immunoprecipitation of
cFLIP enriched for caspase-10 (Figure 4F), confirming that these
two proteins heterodimerize in myeloma.
To investigate whether binding of cFLIPL to caspase-10
promotes caspase-10 activity, we used TAP-Casp10*, enabling
streptavidin precipitation. In the myeloma line SKMM1, we ex-
pressed wild-type TAP-Casp10* or a mutant version with an
amino acid substitution that abrogates protease activity. Precip-
itation of wild-type TAP-Casp10* pulled down a 43 kDa cFLIP
isoform (p43FLIP), which was barely visible in the input lysate
but was detected in anti-cFLIP immunoprecipitation (Figure 4F,
upper panel), suggesting that the association of cFLIPL with
TAP-Casp10* may promote its processing into p43FLIP, either
within the myeloma cells or during the immunoprecipitation (Fig-
ure 4G, lower panel). In contrast, protease-dead TAP-Casp10*
associated with full-length cFLIPL as well as with p43FLIP. The
presence of p43FLIP under these conditions suggested that
protease-dead TAP-Casp10* may associate with endogenous
caspase-10, allowing some cFLIPL cleavage to proceed. This
hypothesis is compatible with the analysis of TAP-Casp10* in
these same immunoprecipitates (Figure 4G, upper panel).
Wild-type TAP-Casp10* was predominantly present as an
47-kD fragment, presumably the product of autocatalytic
cleavage occurring either in the myeloma cell or during the
immunoprecipitation. Protease-dead TAP-Casp10* was mostly
present as the full-length isoform, but some cleaved
TAP-Casp10* was present, potentially due to the presence of
endogenous caspase-10 in the immunoprecipitates.
To test whether cFLIPL might induce the partial autocatalytic
cleavage of caspase-10, we purified TAP-Casp10* using strep-Figure 3. Caspase-10 Inhibition in Myeloma Induces Autophagy
(A) Cell cycle distribution of KMS12myeloma cells following shCasp10-2 inductio
0 values.
(B) shCasp10-2 was induced in the indicated myeloma lines for 5 days or left u
binding (left). Caspase-3 activation was evaluated by incubation with FITC-DEVD
(0.5 mg/ml) for 4 hr.
(C) Representative electron microscopic images of UTMC2 myeloma cells treate
times. Lower panels show expanded view of the boxed areas in upper panel. Arro
indicate autophagolysosomes with degraded organelles. Scale bars: 1 mm.
(D) Representative confocal images of SKMM1myeloma cells expressingGFP-mC
(red). Scale bar: 10 mm.
(E) LC3-I and LC3-II levels in the indicatedmyeloma lines treated with QVD-OPH (2
E64-d (10 mg/ml) or vehicle in the last 12 hr.
(F) ATG5 or control shRNAs were induced in SKMM1 myeloma cells for 3 days b
more days, followed by immunoblot analysis of LC3, ATG5, and b-actin.
(G) Left: Four myeloma lines (KMS11, KMS12, UTMC2, SKMM1) were infected w
shRNA expression for 3 days before Q-AEVD-OPH (25 mM) exposure. Live GFP
averaged. Error bars showmean ± SEM. *p < 0.05. ATG5 protein level in KMS12 c
Beclin-1 or control shRNAs were induced in KMS12 myeloma cells for 3 days, foll
shRNA+ cells were quantified by FACS. Shown are means from three experiments
was determined by immunoblot.
(H) Myeloma lines were infected with retroviruses expressing the indicated shRNA
GFP together with caspase-10 or control shRNAs. The relative abundance of G
KMS11) were averaged. Error bars show mean ± SEM. Data are representative o
(I) Myeloma and lymphoma lines were treated with 3-MA at the indicated concen
See also Figure S3.tavidin beads from transfected HEK293T cells, which do not
have detectable cFLIPL. Incubation of these TAP-Casp10*-
coated beads with an extract from the SKMM1 myeloma line
pulled down full-length cFLIPL as well as p43FLIP (Figure 4H).
Incubation of TAP-Casp10* with the SKMM1 extract at 4C
yielded primarily the full-length TAP-Casp10*, but also a small
amount of a cleaved 47 kDa TAP-Casp10* fragment, which
was not observed following incubation with a HEK293T extract
(Figure 4H). We next tested whether the processing of cFLIPL
and the cleavage of caspase-10 are temperature-dependent,
as would be expected if these events are due to the enzymatic
activities of caspase-10. Following overnight incubation of
TAP-Casp10*-coated beads with the SKMM1 extract at 4C,
warming to 37C for 10 min significantly increased the cleavage
of caspase-10 and the processing of cFLIPL into p43FLIP (Fig-
ure 4I). Finally, knockdown of cFLIP decreased caspase-10
proteolytic activity in myeloma lines, as did caspase-10 knock-
down (Figure 4J). Together, these data suggest that the interac-
tion between cFLIPL and caspase-10 in myeloma cells promotes
partial activation of caspase-10.
Caspase-10 Protects Myeloma Cells from BCLAF1-
Induced Autophagy
To gain further insight into pathways regulated by caspase-10 in
myeloma, we profiled gene expression following caspase-10
knockdown. BCLAF1, encoding BCL2-associated transcription
factor 1, was the most consistently upregulated gene following
caspase-10 inhibition inmyeloma lines but not in lymphoma lines
(Figure S5A), a finding confirmed by real-time PCR (Figure S5B).
Although caspase-10 is unlikely to directly affect BCLAF1 tran-
scription, these data suggested that BCLAF1 and caspase-10
might participate in a common regulatory pathway in myeloma
cells. We noted that the degree of BCLAF1 protein induction
following caspase-10 knockdown was quantitatively greater
than the degree of BCLAF1 mRNA induction (Figures S5B andn determined by PI labeling and FACS analysis. Results were normalized to day
ntreated. Phosphatidylserine (PS) exposure was monitored by Annexin V-PE
-FMK (right). Apoptosis was induced by treatment with anti-Fas antibody CH11
d with Q-VD-OPH (25 mM), Q-AEVD-OPH (25 mM), or vehicle for the indicated
wheads indicate autophagosomes with a double membrane structure. Arrows
herry-tagged LC3 showing autophagosomes (green + red) and autolysosomes
5 mM) or with vehicle alone for 30 hr, and exposed to pepstatin A (10 mg/ml) plus
efore treating with Q-VD-OPH (25 mM), Q-AEVD-OPH (25 mM), or DMSO for 2
ith retroviruses expressing GFP with ATG5 or control shRNAs and induced for
+, shRNA+ cells were quantified by FACS. Data from all myeloma lines were
ells 4 days after shATG5 induction was determined by immunoblot. Right panel:
owed by treatment with Q-VD-OPH (25 mM) for the indicated times. Live GFP+,
± SEM. *p < 0.05. Beclin-1 protein level 4 days after beclin-1 shRNA induction
s, selected for integration for 4 days, then infected with retroviruses expressing
FP+ cells was measured by FACS. Data from two myeloma lines (U266 and
f three independent experiments.
trations for 72 hr, and viability was determined using MTS assay.
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Figure 4. Myeloma Cell Viability Requires cFLIP
(A) Immunoblot analysis of caspase-10 and b-actin in the indicated lines.
(B) Relative CASP10 mRNA expression levels in human resting blood B cells and BM plasma cells quantified by Affymetrix microarray feature 210955_at using
data from Gutie´rrez et al., 2007. Mean normalized log2 signal values ± SEM are shown.
(C) Immunoblot analysis of caspase-10, IRF4, and b-actin in UTMC2 myeloma cells induced for 4 days to express IRF4, caspase-10, or control shRNAs.
(D) Immunoblot analysis of cFLIP expression in the indicated lines. The ratio of cFLIPL to cFLIPS was quantified by densitometry (bottom).
(E) The indicated lines were infected with retroviruses coexpressing GFP and a cFLIP shRNA. Relative numbers of live GFP+/shRNA+ cells were monitored by
FACS Right: immunoblot analysis of cFLIP in SKMM1 cells after induction of CFLAR or control shRNAs for 4 days.
(F) Caspase-10 or cFLIP immunoprecipitates prepared from KMS12myeloma cells were analyzed by immunoblotting for caspase-10 and cFLIP. Mouse IgG was
used as an immunoprecipitation control and a light chain specific secondary antibody was used to improve reading around 55 kDa. Input proteins were also
analyzed.
(G) Wild-type or protease-dead TAP-Casp10* were affinity purified on streptavidin beads from transduced SKMM1 cells and analyzed by immunoblotting for
caspase-10 and cFLIP. Input extracts were also analyzed.
(H) TAP-Casp10* purified from 293T cells on streptavidin beads was incubated overnight at 4Cwith extracts from SKMM1 or 293T cells, and bound caspase-10
and cFLIP were analyzed by immunoblotting. An apparent cleavage product of caspase-10 is indicated. Input extracts were also analyzed.
(I) TAP-Casp10* on streptavidin beads was incubated overnight at 4C with extracts from the myeloma line SKMM1, then warmed to 37C or kept at 4C for
10 min followed by immunoblot analysis of caspase-10 and cFLIP. Input extracts were also analyzed.
(J) Caspase-10 activity was measured using an AEVD-pNA colorimetric assay in whole cell extracts of SKMM1 and H929 myeloma lines after 4 days of
caspase-10 or cFLIP shRNA induction (mean ± SEM, n = 3).
See also Figure S4.
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Caspase-10 Addiction in MyelomaS5C), suggesting that caspase-10 might control BCLAF1 post-
transcriptionally. Moreover, full-length BCLAF1 protein coex-
isted with various smaller BCLAF1 species in myeloma lines,
whereas full-length BCLAF1 was predominant in lymphoma
lines, raising the possibility that BCLAF1 might be targeted by
a protease in myeloma cells (Figure 5A).442 Cancer Cell 23, 435–449, April 15, 2013 ª2013 Elsevier Inc.Knockdown of caspase-10 in the SKMM1 myeloma line
increased the abundance of full-length BCLAF1 while
decreasing the abundance of several smaller species, suggest-
ing that caspase-10 is responsible for BCLAF1 cleavage in
myeloma (Figure 5B). Similarly, treatment of myeloma lines
with the caspase inhibitor Q-VD-OPH eliminated the smaller
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Caspase-10 Addiction in MyelomaBCLAF1 isoforms, coinciding with an increase in the level of full-
length BCLAF1 (Figure 5C). In contrast, knockdown of caspase-
8 had no effect on BCLAF1 cleavage in myeloma cells
(Figure S5D). Immunoprecipitation of endogenous caspase-10
in SKMM1 myeloma cells enriched for BCLAF1, confirming their
interaction (Figure 5D). However, the amount of endogenous
BCLAF1 that coprecipitated with caspase-10 was low, suggest-
ing that the cleavage of BCLAF1 by caspase-10 may cause the
proteins to disassociate. We therefore expressed the proteolyt-
ically dead form of TAP-Casp10* or, as a control, an unrelated
TAP-tagged protein (MyD88) in myeloma cells (Figure S5E).
Full-length BCLAF1 readily coimmunoprecipitated with this
mutant TAP-Casp10* isoform but not with TAP-MyD88, support-
ing the notion that BCLAF1 is a substrate for caspase-10 in
myeloma (Figure S5E). Of note, the abundance of BCLAF1
cleavage products decreased in cells expressing proteolytically
dead TAP-Casp10*, suggesting that it acts in a dominant nega-
tive fashion, consistent with other data (Figure 2A).
In the MEROPS database of protease cleavage sites (Raw-
lings et al., 2004), the aspartic acid at position 452 of BCLAF1
is predicted to be a caspase-10 cleavage site. To test this, we
sought to compare wild-type BCLAF1 with a mutant isoform in
which this aspartate is replaced by alanine (D452A). However,
initial attempts to produce retroviruses expressing full-length
BCLAF1 were unsuccessful, potentially due to toxicity of
BCLAF1 overexpression in the HEK293T retroviral producer cells
(data not shown). To circumvent this problem, we engineered an
inducible form of BCLAF1 by fusing it to an 18 kDa dihydrofolate
reductase (DHFR)-derived ‘‘destruction’’ domain that targets
fusion proteins for proteasomal degradation (Iwamoto et al.,
2010). Proteins bearing this engineered destruction domain
can be stabilized by the addition of the membrane-permeable
ligand trimethoprim to the culture medium. Using this system,
wild-type and D452A BCLAF1-DHFR were induced in the
SKMM1 myeloma line and the levels of full-length and cleaved
products were assessed by immunoblotting (Figure 5E). Expres-
sion of wild-type BCLAF1-DHFR yielded a 52 kDa fragment that
was not present when the cells were treated with the caspase-10
inhibitor AEVD-OPH. This 52 kDa fragment was not detected in
cells expressing D452A BCLAF1-DHFR, suggesting that D452
is a direct proteolytic target of caspase-10.
BCLAF1 was originally identified as a protein that binds to the
adenoviral Bcl-2 homolog E1B19K as well as to several anti-
apoptotic members of the BCL2 protein family and is toxic
when overexpressed (Kasof et al., 1999; Re´nert et al., 2009).
Indeed, induction of the BCLAF1-DHFR fusion protein was lethal
to three myeloma lines (Figure 5F). We therefore investigated
whether BCLAF1 is involved in the same cell death pathway in
myeloma as caspase-10. We generated two shRNAs targeting
BCLAF1 that lowered its mRNA and protein levels in myeloma
cells without toxicity (Figures S5F–S5H). We stably expressed
these BCLAF1 shRNAs or a control shRNA in three myeloma
lines. In the control lines, expression of a caspase-10 shRNA
was toxic, as expected, but in BCLAF1 knockdown lines, the
toxicity of the caspase-10 shRNA was mitigated (Figure 5G).
BCLAF1 knockdown also blocked the myeloma cell death
caused by Q-VD-OPH or Q-AEVD-OPH (Figure 5H) or cFLIP
depletion (Figure S5I). We conclude that BCLAF1 is an important
cleavage target of caspase-10/c-FLIPL that accumulatesfollowing caspase-10 inhibition, contributing to myeloma cell
death.
We next investigated whether the toxicity of BCLAF1 was
associated with induction of autophagy. Induction of BCLAF1-
DHFR expression in myeloma cells did not induce apoptosis
(Figure S6A) but instead increased LC3-II conversion, consistent
with autophagy (Figure 6A). Moreover, inmyeloma cells express-
ing GFP-LC3, expression of BCLAF1-DHFR increased the
percentage of cells with GFP-LC3 puncta compared with unin-
duced cells or cells bearing a control vector (Figure S6B). Elec-
tron micrographs of BCLAF1-DHFR-expressing cells revealed
many vacuolated cells, with autophagosomes and late autopha-
gic vacuoles visible at higher magnification (Figure 6B). As
observed following caspase-10 inhibition, BCLAF1-
DHFR-expressing cells had mitochondrial condensation and
less endoplasmic reticulum, but the nucleus remained intact
without evident chromatin changes (Figure 6B). We measured
autophagic flux following BCLAF1-DHFR expression using
GFP-mCherry-LC3 (Figure 6C). Control cells had a small number
of LC3+ autophagosomes (yellow) and autolysosomes (red).
Following BCLAF1-DHFR induction, the number of LC3+ auto-
phagosomes increased after 2 days and by 4 days, LC3 was
localized predominantly in autolysosomes. Hence, BCLAF1
overexpression in myeloma cells induces autophagy. Knock-
down of the autophagy regulators ATG5 and ATG7 rescued
myeloma cells from BCLAF1-induced death, demonstrating
that BCLAF1 induces autophagic cell death (Figure 6D).
The previous experiments suggested that the prevention of
autophagic cell death by caspase-10 relies on its ability to cleave
BCLAF1. Earlier work suggested that BCLAF1 binds to anti-
apoptotic BCL2 family members (Kasof et al., 1999), as does
the autophagy inducer beclin-1 (Pattingre et al., 2005). We there-
fore investigated whether caspase-10 activity might control the
association of these two proteins with BCL-2. Beclin-1 could
be co-immunoprecipitated with BCL-2 from myeloma cell
extracts, but treatment of these cells with the caspase inhibitor
Q-VD-OPH reduced this interaction (Figure 6E). By contrast,
trace amounts of BCLAF1 could be detected in BCL-2 immuno-
precipitates from myeloma cells, but caspase inhibition strongly
increased the interaction of these two proteins (Figure 6F). Next,
we expressed BCLAF1-DHFR in myeloma cells and observed
that the amount of beclin-1 that could be coimmunoprecipitated
with BCL-2 decreased (Figure 6G). These data are consistent
with a model in which the increased interaction of BCLAF1 with
BCL2 upon caspase-10 inhibition results in the dissociation of
beclin-1 from BCL-2, thereby initiating autophagy.
DISCUSSION
The identification of caspase-10 as essential for myeloma cell
viability has unveiled a molecular pathway that regulates auto-
phagy. Autophagy is required physiologically in normal plasma
cells to moderate the expansion of the endoplasmic reticulum
and immunoglobulin secretion, thereby maintaining cellular
energy balance (Pengo et al., 2013) (Figure 7A). In addition,
various types of endoplasmic reticulum stress, including mis-
folded proteins, activate the unfolded protein response, which
in turn initiates autophagy (Hetz and Glimcher, 2009; Ogata
et al., 2006). Myeloma cells may inherit the autophagyCancer Cell 23, 435–449, April 15, 2013 ª2013 Elsevier Inc. 443
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Figure 5. BCLAF1 Is a Substrate for Caspase-10
(A) Immunoblot analysis of BCLAF1 in the indicated cell lines.
(B) A caspase-10 shRNA was induced in SKMM1 myeloma cells for the indicated times, and then caspase-10, BCLAF1, and b-actin were analyzed by immu-
noblotting.
(C) The indicated myeloma lines were treated with Q-VD-OPH (25 mM) for the indicated times, followed by immunoblotting for caspase-10, BCLAF1, and b-actin.
(D) Caspase-10 immunoprecipitates prepared from SKMM1 myeloma cells were analyzed by immunoblotting using the indicated antibodies. Mouse IgG was
used as an immunoprecipitation control. Input proteins were also analyzed.
(E) SKMM1 myeloma cells were transduced with retroviruses expressing the wild-type or the D452A mutant BCLAF1 fused to DHFR, BCLAF1, and b-actin were
analyzed by immunoblotting following a 3-day induction of BCLAF1 expression. Data are representative of three experiments.
(legend continued on next page)
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Caspase-10 Addiction in Myelomadependence of normal plasma cells and may also induce auto-
phagy through the unfolded protein response. Indeed, myeloma
cells had ultrastructural features consistent with low-level auto-
phagy under basal conditions. Moreover, pharmacologic or
genetic inhibition of autophagy caused myeloma cells to die,
as previously described (Hoang et al., 2009). On the flip side,
uncontrolled autophagy can reduce cellular viability under
some circumstances, presumably when this catabolic process
reduces the abundance of cellular organelles beyond a critical
point (Galluzzi et al., 2012). Our studies demonstrate that a heter-
odimeric protease composed of caspase-10 and cFLIPL is used
by myeloma cells to balance the prosurvival and prodeath
effects of autophagy.
All myeloma lines tested were caspase-10 dependent, irre-
spective of their underlying genetic abnormality, qualifying this
phenomenon as ‘‘nononcogene addiction’’ (Luo et al., 2009).
The high expression of caspase-10 and cFLIPL in myeloma is
due to the fact that their genes are transactivated by IRF4,
a master regulator of the plasma cell phenotype (Shaffer et al.,
2008). IRF4 levels in myeloma are higher than those in normal
plasma cells due to a positive autoregulatory loop with c-Myc
(Shaffer et al., 2008), driving IRF4 target genes to high levels in
myeloma. By an unknown mechanism, myeloma cells preferen-
tially express the cFLIPL isoform, which promotes caspase-10
activity, and not the cFLIPS isoform, which is inhibitory. These
transcriptional and posttranscriptional influences promote high
expression of caspase-10 and cFLIPL in myeloma, which may
drive their heterodimerization and proteolytic activity. The
present study implies that loss of this caspase-10 proteolytic
activity is one of the many reasons that myeloma cells die
upon IRF4 knockdown (Shaffer et al., 2008).
Caspase-10 inhibition in myeloma cells triggers an autophagic
cell death that is reminiscent in some respects to the death
invoked by caspase-8 inhibition in other cell types (Bell et al.,
2008; Yu et al., 2004). In both cases, cell death can be blocked
by inhibiting components of the autophagic machinery (e.g.,
beclin-1 and ATG5). Caspase-8 also regulates a necrotic death
response, primarily by reducing RIPK3 activity. Caspase-10
does not seem to share this mechanistic feature because
RIPK3 knockdown did not prevent death upon caspase-10 inhi-
bition (data not shown). Caspase-8 itself was not required for
myeloma survival, leading us to conclude that the caspase-10/
cFLIPL protease performs an essential, nonredundant role in
plasmacytic cells that limits the autophagic response.
BCLAF1 emerged from our studies as a potent autophagy
inducer that must be cleaved and inactivated by caspase-10 to
protect myeloma cells from uncontrolled autophagy. By an
unknown mechanism, BCLAF1 was also transcriptionally upre-(F) The indicated myeloma lines were infected with a retrovirus coexpressing mou
trimethoprim was added to stabilize the BCLAF1-DHFR fusion protein. The perc
BCLAF1-DHFR, and normalized to day 0 values.
(G) The indicated myeloma lines were infected with retroviruses expressing a mi
2 days, cells were infected with a retrovirus coexpressing GFP and a caspase-10 s
shCasp10+ cells was measured by FACS. Shown are means ± SEM. BCLAF1 an
shRNA induction.
(H) The indicated myeloma lines were infected with retroviruses expressing a mix o
3 days, and then treated with 25 mM Q-VD-OPH or Q-AEVD-OPH, or with DMSO
normalized to DMSO values. Shown are means ± SEM. *p < 0.05.
See also Figure S5.gulated following caspase-10 inhibition, suggesting an orches-
trated transcriptional and posttranscription regulatory module
that promotes the expression of full-length BCLAF1 under these
circumstances. BCLAF1 function has been enigmatic. While
BCLAF1 binds to anti-apoptotic BCL2 family proteins and can
induce apoptosis when overexpressed in some contexts (Kasof
et al., 1999), cells from BCLAF1-deficient mice do not have
obvious defects in apoptosis (McPherson et al., 2009). In
myeloma cells, BCLAF1 interacted with BCL2, and their associ-
ation increased following caspase-10 inhibition. BCL2 residing
on the endoplasmic reticulum regulates autophagy by seques-
tering the BH3-only protein beclin-1 (Pattingre et al., 2005).
Release of beclin-1 from BCL2, and the subsequent initiation
of autophagy, can be achieved by expression of BH3-only
proteins that compete for binding of beclin-1 to BCL2 (Maiuri
et al., 2007). Hence, it is conceivable that BCLAF1 may induce
autophagy by antagonizing the interaction of beclin-1 with
BCL2 (Figure 7B). Consistent with this hypothesis, caspase-10
inhibition decreased the association of BCL2 with beclin-1 while
increasing its association with BCLAF1. Although plausible,
a variety of other functions have been ascribed to BCLAF1,
including participation in mRNA splicing and transcriptional
repression (Sarras et al., 2010), which could also contribute to
its function in myeloma.
The essential role of caspase-10/cFLIPL in myeloma raises the
possibility that this enzymemight serve as a therapeutic target in
this disease. Functional studies of caspase-10 have been limited
by the fact that this caspase is not encoded in rodent genomes.
Humans with inherited caspase-10 deficiency develop an auto-
immune lymphoproliferative disorder, apparently due to the
absence of pro-apoptotic caspase-10 signaling (Wang et al.,
1999). Full autoproteolytic processing of caspase-10 involves
two internal cleavage sites and releases the active dimer that
initiates apoptosis (Wachmann et al., 2010). The association of
cFLIPL with caspase-10 in myeloma cells appears to prevent
one of these two cleavage events, yielding a heterodimer
composed of a partially cleaved caspase-10 subunit and
a p43FLIP subunit. Conceivably, small molecules could be iden-
tified that would inhibit this caspase-10/cFLIPL heterodimer but
not the fully cleaved caspase-10 homodimer. Such inhibitors
might induce autophagic cell death of myeloma cells while not
blocking caspase-10-dependent physiological apoptosis.EXPERIMENTAL PROCEDURES
Molecular Biology
The retroviral constructs for shRNA expression and the design of shRNA library
sequences have been described (Ngo et al., 2006). shRNA target sequencesse CD8a and BCLAF1-DHFR, or with empty vector. At time 0, the DHFR ligand
entage of LyT2+ cells was measured by FACS over time following induction of
x of two BCLAF1 shRNAs or a control shRNA. Following shRNA induction for
hRNA or a control shRNA. Following shRNA induction, the percentage of GFP+
d a-tubulin were analyzed by immunoblotting in SKMM1 cells after 4 days of
f two BCLAF1 shRNAs or a control shRNA, induced to express the shRNAs for
for the indicated times. Live calcein+, PI cells were quantified by FACS, and
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Figure 6. BCLAF1 Promotes Autophagy
(A) Immunoblot analysis of LC3, BCLAF1, and b-actin in SKMM1 myeloma cells induced to express BCLAF1-DHFR for the indicated times. The autophagy-
associated LC3-II isoform is indicated.
(B) Electron micrographs of UTMC2 myeloma cells induced to express BCLAF1-DHFR for 3 days, or transduced with empty vector. Higher-power images
(bottom) corresponding to boxed areas show autophagosomes with double membrane structure (arrows) and autophagolysosomes with degraded organelles
(arrowheads). Scale bars: 1 mm.
(C) Representative confocal images of SKMM1 myeloma cells expressing mCherry-GFP-LC3B and induced for BCLAF1-DHFR expression for the indicated
times. Scale bar: 10 mm.
(D) Twomyeloma lines (SKMM1, KMS12) were first infected with retroviruses expressing BCLAF1-DHFR or with an empty vector, superinfected with retroviruses
expressing an ATG5, ATG7, or control shRNAs and induced for shRNA expression for 2 days prior to BCLAF1-DHFR induction for the indicated periods of time.
Live calcein+, PI cells were quantified by FACS and data were normalized to DMSO values. Shown are means ± SEM. *p < 0.05. Data are representative of three
independent experiments.
(E) KMS12myeloma cells were treated with Q-VD-OPH (25 mM) or with vehicle for 48 hr, and then BCL2 immunoprecipitates were analyzed by immunoblotting for
beclin-1 and BCL2. Mouse IgG was used as an immunoprecipitation control. Input proteins were also analyzed.
(legend continued on next page)
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Figure 7. Model of Caspase-10 Control of Autophagic Cell Death in Multiple Myeloma
(A) Caspase-10 maintains the proper balance between prosurvival and prodeath autophagic responses.
(B) BCLAF1 upregulation following caspase-10 inhibition leads to the dissociation of beclin-1 from BCL2, thereby augmenting autophagy.
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Study Subjects
Bone marrow (BM) aspirate specimens were collected from patients with
newly diagnosed multiple myeloma. After Ficoll–Hypaque gradient centrifuga-
tion, plasma cells were isolated from the mononuclear-cell fraction by immu-
nomagnetic bead selection with the use of a monoclonal mouse antihuman
CD138 antibody (Miltenyi-Biotec). Plasma cell purity (>90%) was confirmed
by two-color flow cytometry using CD138+/CD45 and CD38+/CD45 anti-
bodies (Becton Dickinson, San Jose, CA). All subjects provided written
informed consent approving use of their samples for research purposes in
accordance with the Declaration of Helsinki. All protocols were approved by
the Institutional Review Board of the National Cancer Institute.
Cell Culture
Myeloma cell lines, lymphoma cell lines, and the human stromal cell line HS-5
(kindly provided by Dr. Selina Chen-Kiang, Weill Cornell Medical College, New
York, NY) were maintained as described in the Supplemental Experimental
Procedures. For efficient retroviral infection and transduction, cell lines were
engineered to express the murine ecotropic retroviral receptor and the bacte-
rial tetracycline repressor (TETR) (Ngo et al., 2006).
Caspase-10 Activity
One hundred microgram aliquots of cell lysate were prepared and used follow-
ing the manufacturer’s recommendations to assay caspase-10 activity using
the AEVD-pNA substrat in a colorimetric assay (Biovision, Mountain View, CA).(F) SKMM1 myeloma cells were induced to express shBCLAF1-1 for 3 days prio
noprecipitates were analyzed by immunoblotting for BCLAF1 and BCL2.
(G) SKMM1 myeloma cells were transduced with BCLAF1-DHFR or with an empt
prepared using anti-BCL2 antibody-conjugated agarose beads were analyzed by
from SKMM1 cells transduced with an empty vector was also analyzed as were
See also Figure S6.Cell Viability and Cell Death Measurement
To assess toxicity of a shRNA, retroviruses that coexpressed GFP were used
as described (Ngo et al., 2006). In brief, flow cytometry was performed 2 days
after retroviral infection to determine the initial GFP-positive proportion of
live cells for each shRNA, then cells were subsequently cultured with doxycy-
cline to induce shRNA and sampled over time. The GFP+ proportion at each
time was monitored using a FACScan (Becton Dickinson) and normalized to
the initial value. For enumeration of live cells after vLyt-2 retroviral transduc-
tions, measured aliquots of cultures were stained on ice for 15 min with PE-
conjugated antimouse CD8a (BD PharMingen). The LyT2+ proportion was
monitored by flow cytometry and normalized to the initial value. To assess
Q-VD-OPH andQ-AEVD-OPH toxicity, cells were incubated with green calcein
and propidium iodide (PI) at 37C for 30 min. Flow count fluorospheres
(Beckman Coulter, Fullerton, CA) were used to quantify the number of living
cells (calcein positive, PI negative) with flow cytometry. Under each condition,
20,000 microbeads were added just prior to the analysis, 2,000 microbeads
were collected, and the number of living cells was determined using a FACS-
can (Becton Dickinson).
Phosphatidylserine exposure and in situ labeling of active caspase-3 were
measured by flow cytometry using a FACScan (BD Biosciences) and data
were processed with the CellQuest program (BD Biosciences). See Supple-
mental Experimental Procedures for details.
Immunoprecipitations, Pulldown Assays, and Immunblot Analysis
TAP-tag affinity purifications, immunoprecipitations, and pulldown assays
were performed using standard procedures from nondenaturing cell extracts.
See Supplemental Experimental Procedures for details.r to Q-VD-OPH (25 mM) or vehicle treatment for 36 hr, and then BCL2 immu-
y vector and induced to express BCLAF1-DHFR for 48 hr. Immunoprecipitates
immunoblotting for BCLAF1, Beclin-1, or BCL2. A control precipitate prepared
lysates.
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Cell pellets were fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer
(Electron Microscopy Sciences, Hatfield, PA). The cells were washed with
0.1 M sodium cacodylate buffer and postfixed with 1% osmium tetroxide/
0.8% potassium ferricyanide in 0.1 M sodium cacodylate, followed by 1%
tannic acid in distilled water, and stained en bloc with 1% aqueous uranyl
acetate. The pellets were then dehydrated in graded ethanol series, infiltrated,
and embedded in Spurr’s resin. Thin sections were cut on a UC6 ultramicro-
tome (Leica Microsystems, Vienna, Austria) and stained with 4% aqueous
uranyl acetate and Reynold’s lead citrate prior to viewing on a Tecnai BioTwin
Spirit TEM (FEI, Hillsboro, OR). Digital images were acquired with a Hama-
matsu XR-100 digital camera system (AMT, Danvers, MA.).
Fluorescence Microscopy and Confocal Microscopy
Multiple myeloma cells were infected with a retrovirus expressing LC3-GFP
fusion protein. After induction of autophagy, samples were examined using
an epifluorescent microscope (Olympus BX61). For confocal microscopy,
1–23 105 cells were seeded on bottom glass 35-mm dishes coated with poly-
lysine (MatTek Corp.) for 30 min at room temperature. The cells were fixed with
4% paraformaldehyde for 30 min at room temperature and washed two times
in PBS. Nuclear counterstaining was performed with 0.1 mg/ml 4,6-diamidino-
2-phenylindole (DAPI) in PBS for 10 min. Cells were washed two times with
PBS and were examined using a Zeiss LSM510 laser scanning confocal
microscope.
ACCESSION NUMBERS
Gene expression profiling data have been deposited in GEO under accession
number GSE43878.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and Supplemental Experimental
Procedures and can be found with this article online at http://dx.doi.org/10.
1016/j.ccr.2013.02.017.
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